See the impact of ENTYVIO (vedolizumab) in reducing symptoms and achieving remission for Crohn’s disease. See Safety and Prescribing Information.

Learn more about ENTYVIO® (vedolizumab), a biologic treatment for moderate to severe ulcerative colitis or Crohn's disease in adults.

Entyvio (vedolizumab) has been approved by the U.S. Food and Drug Administration (FDA) for inducing and maintaining clinical response, inducing and maintaining clinical remission, …

Oct 20, 2017 · The Entyvio Patient Assistance Program offers patients who qualify the opportunity to lower their vedolizumab cost. Prescription Hope provides access to the Entyvio Patient …

Nov 19, 2025 · With continued treatment, Entyvio can significantly relieve symptoms, induce remission, and reduce or stop the use of corticosteroids. When people are in remission, …

5 days ago · This represents 100% consensus among guideline authors 1. The Canadian Association of Gastroenterology similarly issues a strong recommendation (moderate-quality …

How Was It Studied? The effect of Entyvio on disease remission was studied in people with moderate to severe ulcerative colitis and Crohn’s disease. People in these studies were …

May 11, 2023 · In this real-world comparative effectiveness study, we observe similar rates of clinical remission at 6 and 12 months after initiating first-line vedolizumab or ustekinumab …

Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Takeda Oncology for the treatment of ulcerative colitis and Crohn's disease. [5]

EntyvioConnect provides financial assistance, resources, and expert guidance to support you throughout every step of your ENTYVIO treatment journey.